BioArctic and Eisai Showcase Long-Term Lecanemab Use and New Parkinson’s Trial Tools

BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an announcement.

BioArctic’s partner Eisai reported new real-world data at the AD/PD 2026 congress showing strong long-term treatment persistence for intravenous lecanemab in early Alzheimer’s patients in the U.S., with most remaining on therapy beyond 18 months, mirroring high continuation rates seen in Phase 3 trials and suggesting sustained engagement with the drug in routine practice. BioArctic also highlighted mechanistic data on lecanemab’s selective targeting of soluble amyloid-beta protofibrils and the use of an alpha-synuclein seed amplification assay to stratify patients in the exidavnemab Parkinson’s and multiple system atrophy trial, underscoring its broader ambitions in disease-modifying neurodegenerative therapies and the growing global footprint and formulation diversification of Leqembi.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK349.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

More about BioArctic AB Class B

BioArctic AB is a Swedish biopharmaceutical company focused on neurodegenerative diseases, developing antibody-based therapies for conditions such as Alzheimer’s and Parkinson’s. Its lead partnered product, lecanemab (marketed as Leqembi by Eisai), targets amyloid-beta in early Alzheimer’s disease, while exidavnemab is being explored for Parkinson’s disease and multiple system atrophy.

YTD Price Performance: -1.54%

Average Trading Volume: 202,003

Technical Sentiment Signal: Strong Buy

Current Market Cap: SEK27.12B

Learn more about BIOA.B stock on TipRanks’ Stock Analysis page.